Suppression of complement regulatory proteins (CRPs) exacerbates experimental autoimmune anterior uveitis (EAAU)

Journal of Immunology

Volumn 176, Issue 12, 2006, Pages 7221-7231

  Jha, Purushottam ^a   Sohn, Jeong Hyeon ^b   Xu, Qin ^a   Wang, Yali ^b   Kaplan, Henry J ^b   Bora, Puran S ^a   Bora, Nalini S ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; C REACTIVE PROTEIN; CD4 ANTIGEN; CD59 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT REGULATORY PROTEIN; PROTEIN CRYY; REGULATOR PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; DISEASE EXACERBATION; EYE INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; IRIDOCYCLITIS; MALE; MEMBRANE BINDING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION;

EID: 33744906052     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.12.7221     Document Type: Article

References (60)

1. Morgan, B. P., and M. J. Walport. 1991. Complement deficiency and disease. Immunol. Today 12: 301-306.
2. Atkinson, J. P., and T. Fairies. 1987. Separation of self from non-self in the complement system. Immunol. Today 8: 212-215.
3. Lublin, D. M., and J. P. Atkinson. 1991. Decay-accelerating factor and membrane cofactor protein. Curr. Top. Microbiol. Immunol. 153: 123-145.
4. Liszewski, M. K., T. W. Post, and J. P. Atkinson. 1991. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu. Rev. Immunol. 9: 431-455.
5. Liszewski, M. K., and J. P. Atkinson. 1992. Membrane cofactor protein. Curr. Top. Microbiol. Immunol. 178: 45-60.
6. Holguin, M. H., and C. J. Parker. 1992. Membrane inhibitor of reactive lysis. Curr. Top. Microbiol. Immunol. 178: 61-85.
7. Spicer, A. P., M. F. Seldin, and S. J. Gendler. 1995. Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes: duplicated genes encode glycosylphophatidylinositol-anchored and transmembrane forms. J. Immunol. 155: 3079-3083.
8. Tsujimura, A., K. Shida, M. Kitamura, M. Nomura, J. Takeda, H. Tanaka, M. Matsumoto, K. Matsumiya, A. Okuyama, Y. Nishimune, et al. 1998. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells. Biochem. J. 330: 163-168.
9. Kim, Y. U., T. Kinoshita, H. Molina, D. Hourcade, T. Seya, L. M. Wagner, and V. M. Holers. 1995. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J. Exp. Med. 181: 151-159.
10. Quigg, R. J., C. F. Lo, J. J. Alexander, A. E. Sneed III, and G. Moxley. 1995. Molecular characterization of rat Crry: widespread distribution of two alternative forms of Crry mRNA. Immunogenetics 42: 362-367.
11. Hughes, T. R., S. J. Piddlesden, J. D. Williams, R. A. Harrison, and B. P. Morgan. 1992. Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. Biochem. J. 284: 169-176.
12. Funabashi, K., N. Okada, S. Matsuo, T. Yamamoto, B. P. Morgan, and H. Okada. 1994. Tissue distribution of complement regulatory membrane proteins in rats. Immunology 81: 444-451.
13. Sohn, J. H., H. J. Kaplan, H. J. Suk, P. S. Bora, and N. S. Bora. 2000. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. Invest. Ophthalmol. Vis. Sci. 41: 3492-3502.
14. Bloch-Michel, E., and R. B. Nussenblatt. 1987. International uveitis study group recommendations for the evaluation of intraocular inflammatory disease. Am. J. Ophthalmol. 103: 234-235.
15. Nussenblatt, R. B., S. M. Whitcup, and A. G. Palestine. 1996. Uveitis: Fundamentals and Clinical Practice, 2nd Ed. Mosby, St. Louis, p. 413.
16. Bora, N. S., M. D. Woon, M. T. Tandhasetti, T. P. Cirrito, and H. J. Kaplan. 1997. Induction of experimental autoimmune anterior uveitis by a self-antigen: melanin complex without adjuvant. Invest. Ophthalmol. Vis. Sci. 38: 2171-2175.
17. Bora, N. S., J. H. Sohn, S. G. Kang, J. M. Cruz, H. Nishihori, H. J. Suk, Y. Wang, H. J. Kaplan, and P. S. Bora. 2004. Type I collagen is the autoantigen in experimental autoimmune anterior uveitis. J. Immunol. 172: 7086-7094.
18. Jha, P., J. H. Sohn, X. Qin, H. Nishihori, Y. Wang, S. Nishihori, B. Manickam, H. J. Kaplan, P. S. Bora, and N. S. Bora. 2006. Complement system plays a critical role in the development of experimental autoimmune anterior uveitis (EAAU). Invest. Ophthalmol. Vis. Sci. 47: 1030-1038.
19. Turnberg, D., M. Botto, J. Warren, B. P. Morgan, M. J. Walport, and H. T. Cook. 2003. CD59a deficiency exacerbates accelerated nephrotoxic nephritis in mice. J. Am. Soc. Nephrol. 14: 2271-2279.
20. Mead, R. J., J. W. Neal, M. R. Griffiths, C. Linington, M. Botto, H. Lassmann, and B. P. Morgan. 2004. Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. Lab. Invest. 84: 21-28.
21. Rickman, D. W., and C. B. Rickman. 1996. Suppression of trkB expression by antisense oligonucleotides alters a neuronal phenotype in the rod pathway of the developing rat retina. Proc. Natl. Acad. Sci. USA 93: 12564-12569.
22. Sato, Y., T. Ajiki, S. Inoue, J. Fujishiro, H. Yoshino, Y. Igarashi, Y. Hakamata, T. Kaneko, T. Murakamid, and E. Kobayashi. 2005. Gene silencing in rat-liver and limb grafts by rapid injection of small interference RNA. Transplantation 79: 240-243.
23. Hori, Y., K. Yamada, N. Hanafusa, T. Okuda, N. Okada, T. Miyata, W. G. Couser, K. Kurokawa, T. Fujita, and M. Nangaku. 1999. Crry, a complement regulatory protein, modulates renal interstitial disease induced by proteinuria. Kidney Int. 56: 2096-2106.
24. Endoh, M., M. Yamashina, H. Ohi, K. Funahashi, T. Ikuno, T. Yasugi, J. P. Atkinson, and H. Okada. 1993. Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues. Clin. Exp. Immunol. 94: 182-188.
25. Jones, J., I. Laffafian, A. M. Cooper, B. D. Williams, and B. P. Morgan. 1994. Expression of complement regulatory molecules and other surface markers on neutrophils from synovial fluid and blood of patients with rheumatoid arthritis. Br. J. Rheumatol. 33: 707-712.
26. Davies, M. E., A. Horner, B. E. Loveland, and I. F. McKenzie. 1994. Upregulation of complement regulators MCP (CD46), DAF (CD55) and protectin (CD59) in arthritic joint disease. Scand. J. Rheumatol. 23: 316-321.
27. Varsano, S., I. Frolkis, and D. Ophir. 1995. Expression and distribution of cell-membrane complement regulatory glycoproteins along the human respiratory tract. Am. J. Respir. Crit. Care Med. 152: 1087-1093.
28. Makidono, C., M. Mizuno, J. Nasu, S. Hiraoka, H. Okada, K. Yamamoto, T. Fujita, and Y. Shiratori. 2004. Increased serum concentrations and surface expression on peripheral white blood cells of decay-accelerating factor (CD55) in patients with active ulcerative colitis. J. Lab. Clin. Med. 143: 152-158.
29. Tomita, N., and R. Morishita. 2004. Antisense oligonucleotides as a powerful molecular strategy for gene therapy in cardiovascular diseases. Curr. Pharm. Des. 10: 797-803.
30. Karras, J. G., K. McGraw, R. A. McKay, S. R. Cooper, D. Lerner, T. Lu, C. Walker, N. M. Dean, and B. P. Monia. 2000. Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma. J. Immunol. 16: 5409-5415.
31. Machen, J., J. Harnaha, R. Lakomy, A. Styche, M. Trucco, and N. Giannoukakis. 2004. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J. Immunol. 173: 4331-4341.
32. Makino, N., M. Sugano, S. Ohtsuka, and S. Sawada. 1998. Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats. Hypertension 31: 1166-1170.
33. Kumasaka, T., W. M. Quinlan, N. A. Doyle, T. P. Condon, J. Sligh, F. Takei, A. Beaudet, C. F. Bennett, and C. M. Doerschuk. 1996. Role of the intercellular adhesion molecule-1(ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice. J. Clin. Invest. 97: 2362-2369.
34. Lee, Y. H., I. J. Moon, B. Hur, J. H. Park, K. H. Han, S. Y. Uhm, Y. J. Kim, K. J. Kang, J. W. Park, Y. B. Seu, et al. 2005. Gene knockdown by large circular antisense for high-throughput functional genomics. Nat. Biotechnol. 23: 591-599.
35. Dorn, G., S. Patel, G. Wotherspoon, M. Hemmings-Mieszczak, J. Barclay, F. J. Natt, P. Martin, S. Sevan, A. Fox, P. Ganju, et al. 2004. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 32: e49.
36. Reich, S. J., J. Fosnot, A. Kuroki, W. Tang, X. Yang, A. M. Maguire, J. Bennett, and M. J. Tolentino. 2003. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9: 210-216.
37. Kim, B., Q. Tang, P. S. Biswas, J. Xu, R. M. Schiffelers, F. Y. Xie, A. M. Ansari, P. V. Scaria, M. C. Woodle, P. Lu, and B. T. Rouse. 2004. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am. J. Pathol. 165: 2177-2185.
38. Davidson, B. L., and H. L. Paulson. 2004. Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol. 3: 145-149.
39. Shuey, D. J., D. E. McCallus, and T. Giordano. 2002. RNAi: gene-silencing in therapeutic intervention. Drug. Discov. Today 7: 1040-1046.
40. Zhang, Y., Y. F. Zhang, J. Bryant, A. Charles, R. J. Boado, and W. M. Pardridge. 2004. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 10: 3667-3677.
41. Koffler, D., G. Biesecker, B. Noble, G. A. Andres, and A. Martinez-Hernandez. 1983. Localization of the membrane attack complex (MAC) in experimental immune complex glomerulonephritis. J. Exp. Med. 157: 1885-1905.
42. Gerl, V. B., J. Bohl, S. Pitz, B. Stoffelns, N. Pfeiffer, and S. Bhakdi. 2002. Extensive deposits of C3d and C5b-9 in the choriocapillaris of eyes of patients with diabetic retinopathy. Invest. Opthalmol. Vis. Sci. 43: 1104-1108.
43. Bora, P. S., J. H. Sohn, J. M. Cruz, P. Jha, H. Nishihori, Y. Wang, S. Kaliappan, H. J. Kaplan, and N. S. Bora. 2005. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J. Immunol. 174: 491-497.
44. Quigg, R. J., B. P. Morgan, V. M. Holers, S. Adler, A. E. Sneed III, and C. F. Lo. 1995. Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells. Kidney Int. 48: 412-421.
45. Matsuo, S., S. Ichida, H. Takizawa, N. Okada, L. Baranyi, A. Iguchi, B. P. Morgan, and H. Okada. 1994. In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats. J. Exp. Med. 180: 1619-1627.
46. Mizuno, M., K. Nishikawa, R. M. Goodfellow, S. J. Piddlesden, B. P. Morgan, and S. Matsuo. 1997. The effects of functional suppression of a membrane-bound complement regulatory protein, CD59, in the synovial tissue in rats. Arthritis Rheum. 40: 527-533.
47. Bardenstein, D. S., C. J. Cheyer, C. Lee, E. Cocuzzi, M. Mizuno, N. Okada, and M. E. Medof. 2001. Blockage of complement regulators in the conjunctiva and within the eye leads to massive inflammation and iritis. Immunology 104: 423-430.
48. Jarvelainen, H. A., A. Vakeva, K. O. Lindros, and S. Meri. 2002. Activation of complement components and reduced regulator expression in alcohol-induced liver injury in the rat. Clin. Immunol. 105: 57-63.
49. Kaminski, H. J., Z. Li, C. Richmonds, F. Lin, and M. E. Medof. 2004. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp. Neurol. 189: 333-342.
50. Matsuo, S., H. Nishikage, F. Yoshida, A. Nomura, S. J. Piddlesden, and B. P. Morgan. 1994. Role of CD59 in experimental glomerulonephritis in rats. Kidney Int. 46: 191-200.
51. He, C., M. Imai, H. Song, R. J. Quigg, and S. Tomlinson. 2005. Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephritic syndrome and demonstrate a key role for C5b-9. J. Immunol. 174: 5750-5757.
52. Watanabe, M., Y. Morita, M. Mizuno, K. Nishikawa, Y. Yuzawa, N. Hotta, B. P. Morgan, N. Okada, H. Okada, and S. Matsuo. 2000. CD59 protects rat kidney from complement mediated injury in collaboration with Crry. Kidney Int. 58: 1569-1579.
53. Mizuno, M., K. Nishikawa, O. B. Spiller, B. P. Morgan, N. Okada, H. Okada, and S. Matsuo. 2001. Membrane complement regulators protect against the development of type II collagen-induced arthritis in rats. Arthritis Rheum. 44: 2425-2434.
54. Turnberg, D., M. Botto, M. Lewis, W. Zhou, S. H. Sacks, B. P. Morgan, M. J. Walport, and H. T. Cook. 2004. CD59a deficiency exacerbates ischemia-reperfusion injury in mice. Am. J. Pathol. 165: 825-832.
55. Iwata, F., T. Job, T. Tada, N. Okada, B. P. Morgan, Y. Yokoyama, and M. Itoh. 1999. Role of complement regulatory membrane proteins in ischaemia-reperfusion injury of rat gastric mucosa. J. Gastroenterol. Hepatol. 14: 967-972.
56. Molina, H., T. Miwa, L. Zhou, B. Hilliard, D. Mastellos, M. A. Maldonado, J. D. Lambris, and W. C. Song. 2002. Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor. Blood 100: 4544-4549.
57. Sogabe, H., M. Nangaku, Y. Ishibashi, T. Wada, T. Fujita, X. Sun, T. Miwa, M. P. Madaio, and W. C. Song. 2001. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J. Immunol. 167: 2791-2797.
58. Lin, F., D. Spencer, D. A. Hatala, A. D. Levine, and M. E. Medof. 2004. Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: role for complement in inflammatory bowel disease. J. Immunol. 172: 3836-3841.
59. Miwa, T., M. A. Maldonado, L. Zhou, X. Sun, H. Y. Luo, D. Cai, V. P. Werth, M. P. Madaio, R. A. Eisenberg, and W. C. Song. 2002. Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am. J. Pathol. 161: 1077-1086.
60. Yamada, K., T. Miwa, J. Liu, M. Nangaku, and W. C. Song. 2004. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J. Immunol. 172: 3869-3875.